Listen

Description

How can softer materials make implantable brain-computer interfaces safer, more stable and clinically useful? In this episode of The Business of Neurotech, Adam Fraser is joined by Dr Paul Le Floch, co-founder and CEO of Axoft, to explore how his materials science background led to Fleuron, a soft neural interface platform designed to reach deep brain regions while maintaining high-density recordings. Dr Le Floch explains why Axoft is initially focusing on disorders of consciousness, how the company is taking a stepwise path through FDA clearance and what its early clinical work revealed about turning novel biomaterials into medical devices. He also discusses the realities of raising a $55 million Series A, competing in a fast-moving BCI market, financing research through materials sales and learning to pitch a long-term vision as a scientist-founder. Tune in to learn what it takes to build an invasive BCI company focused on better materials, unmet clinical needs and patient impact.

Key Points From This Episode:

Links Mentioned in Today’s Episode:

Dr Paul Le Floch on LinkedIn

Axoft

Axoft on LinkedIn

Episode 5: Naveen Rao Talks Neurotech Market Dynamics

Episode 8: Nicolas Vachicouras Talks BCI Market Dynamics and Start Up Life

Episode 12: Matt Angle Talks Paradromics and BCI Market Dynamics

Mass General Brigham

FDA Breakthrough Devices Program

iBCI Collaborative Community (iBCI-CC)

Adam Fraser on LinkedIn

Omniscient Neurotechnology

The Business of Neurotech Podcast